Diffuse Diabetic Macular Edema
6
0
0
1
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 65/100
16.7%
1 terminated out of 6 trials
50.0%
-36.5% vs benchmark
50%
3 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (6)
POSTERIOR SUB-TENON'S Avastin
Vitrectomy and Bevacizumab for Diffuse Diabetic Macular Edema
Vitrectomy Without Internal Limiting Membrane Removal in the Treatment of Diffuse Diabetic Macular Edema: a Comparative Kenalog Vs Bevacizumab Intravitreal Injection Vs Control Study
Safety Study of iCo-007 Intravitreal Injection to Treat Diabetic Macular Edema
Triple Therapy for Diffuse Diabetic Macular Edema
Intravitreal Diclofenac Versus Avastin as Primary Treatment of Diffuse Diabetic Macular Edema